Phase 3 Study of IV to Oral 6-Day Tedizolid Phosphate Compared With 10-day Comparator in Subjects 12 to < 18 Years With cSSTI

Trial Profile

Phase 3 Study of IV to Oral 6-Day Tedizolid Phosphate Compared With 10-day Comparator in Subjects 12 to < 18 Years With cSSTI

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Tedizolid (Primary) ; Tedizolid (Primary) ; Cefalexin; Cefazolin; Clindamycin; Clindamycin; Flucloxacillin; Linezolid; Vancomycin
  • Indications Skin and soft tissue infections
  • Focus Adverse reactions; Registrational
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 01 Aug 2017 Planned End Date changed from 18 Jan 2018 to 7 Feb 2019.
    • 01 Aug 2017 Planned primary completion date changed from 18 Jan 2018 to 7 Feb 2019.
    • 02 May 2017 Planned End Date changed from 7 Feb 2019 to 18 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top